Company Number: 14401879

Analysis Date: 2025-07-20 14:11 UTC

1. Credit Opinion: DECLINE
   Anthea Pharma Limited is a very recently incorporated private limited company (since October 2022) with dormant status accounts and minimal financial activity. The company shows negligible revenues or assets (£1,000 debtors and net assets) and no recorded profits or cash flows. The absence of trading history and operating income means there is no evidence of the ability to service debt or repay loans. Additionally, the company operates in a highly regulated pharmaceutical wholesale and manufacturing sector, which typically requires substantial working capital and operational scale to be creditworthy. Without trading accounts or financial performance, the credit risk is high and approval for lending or credit facilities is not recommended at this stage.

2. Financial Strength:
   The balance sheet is extremely limited and reflects a dormant company status. Total current assets and net current assets stand at £1,000, with no fixed assets reported. Shareholders’ funds are equal to £1,000, representing minimal capital investment. There are no liabilities disclosed, but this also indicates no operating activity or financial commitments. This very thin capital base and lack of asset backing do not support financial resilience or capacity to absorb losses.

3. Cash Flow Assessment:
   There is no disclosed cash or cash equivalents in the financial statements, and the only current assets are debtors of £1,000. The company does not report any profit and loss figures or cash flow statements, consistent with dormant status filings. This lack of liquidity and working capital means the company cannot self-fund operations or meet short-term obligations independently. Cash flow visibility is effectively non-existent.

4. Monitoring Points:

• Monitor future filings for the first set of trading accounts to evaluate revenue generation, gross margins, and operating expenses.
• Watch for any increase in current assets, especially cash balances, to assess liquidity improvements.
• Review management commentary or strategic reports once trading begins to understand business plans and risk management.
• Track director changes or any external funding injections that may enhance financial strength.